Datapoint: CVS to Remove Humira From Most National Commercial Formularies

CVS Health Corp. announced on Jan. 3 that it would remove Humira (adalimumab) from CVS Caremark’s major national commercial template formularies and cover the drug’s biosimilars, effective April 1. The PBM said customers with Choice and Standard Opt Out commercial formularies would continue to have an option to have Humira on their formularies. CVS also noted that AbbVie, which manufactures Humira, will supply a co-branded adalimumab biosimilar to Cordavis, a wholly owned CVS biosimilar-focused subsidiary that launched this year. Nearly 90% of Caremark’s 25.3 million commercial pharmacy lives currently have preferred access to Humira, largely with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 1/8/24

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 21

Datapoint: Cigna, HelloFresh Partner on Meal Kit Benefits

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 20

Datapoint: SCAN, CareOregon Nix Merger Plans

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 15

Datapoint: AbbVie Completes ImmunoGen Deal

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today